Norman P S, Nicodemus C F, Creticos P S, Wood R A, Eggleston P A, Lichtenstein L M, Kagey-Sobotka A, Proud D
Johns Hopkins Asthma and Allergy Center, Johns Hopkins University School of Medicine, Baltimore, Md. 21224, USA.
Int Arch Allergy Immunol. 1997 May-Jul;113(1-3):224-6. doi: 10.1159/000237553.
Peptides have been designed to be T cell tolerogenic for the principal allergens of the cat. These have been administered in several dosage programs to cat-sensitive patients in multicenter blinded studies. In contrast to proteins in standard extracts, IgE sensitization to peptides is an uncommon event. Pretreatment prick tests with peptides will identify the occasional sensitized patient. Other side reactions consist of allergic symptoms occurring on the day of injections. These become less severe with subsequent injections and are easily treatable with antihistamines or bronchodilators, depending on the symptoms. Treatment with cat peptides ameliorated symptoms that occur upon exposure to cats 1-6 or more weeks later. A 2-week course of 4 injections is the most effective of the regimens so far tried. T-cell-active peptides offer a promising low-risk alternative for specific treatment of respiratory allergies.
已设计出对猫的主要过敏原具有T细胞耐受性的肽。在多中心盲法研究中，已将这些肽以几种剂量方案给予对猫敏感的患者。与标准提取物中的蛋白质不同，对肽的IgE致敏是罕见事件。用肽进行预处理点刺试验将识别出偶尔致敏的患者。其他副作用包括注射当天出现的过敏症状。随着后续注射，这些症状会减轻，并且根据症状，用抗组胺药或支气管扩张剂很容易治疗。用猫肽治疗可改善1至6周或更长时间后接触猫时出现的症状。4次注射的2周疗程是迄今为止所尝试方案中最有效的。T细胞活性肽为呼吸道过敏的特异性治疗提供了一种有前景的低风险替代方法。
